Comparative Pharmacology
Head-to-head clinical analysis: ANOQUAN versus LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANOQUAN versus LIDOCAINE HYDROCHLORIDE 0 2 IN DEXTROSE 5.
ANOQUAN vs LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Guanabenz is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased peripheral vascular resistance and lowered blood pressure.
Lidocaine is a local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
100 mg orally twice daily
1-1.5 mg/kg IV bolus over 2-3 minutes, followed by continuous IV infusion of 1-4 mg/min for ventricular arrhythmias; maximum 3 mg/kg (or 200-300 mg) over 1 hour.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 4-6 hours) or hepatic impairment (up to 5-7 hours).
Renal excretion accounts for approximately 70% of the dose (50% as unchanged drug, 20% as inactive metabolites); biliary/fecal excretion accounts for 30%.
Renal: ~90% as metabolites and <10% unchanged. Biliary/fecal: minor (<1%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)